Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II.

Details

Ressource 1Download: 29690620_BIB_9F6BA65930B8.pdf (337.36 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_9F6BA65930B8
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II.
Journal
Antibiotics
Author(s)
Sybesma W., Rohde C., Bardy P., Pirnay J.P., Cooper I., Caplin J., Chanishvili N., Coffey A., De Vos D., Scholz A.H., McCallin S., Püschner H.M., Pantucek R., Aminov R., Doškař J., Kurtbӧke D.İ.
Working group(s)
Expert round table on acceptance and re-implementation of bacteriophage therapy
ISSN
2079-6382 (Print)
ISSN-L
2079-6382
Publication state
Published
Issued date
23/04/2018
Peer-reviewed
Oui
Volume
7
Number
2
Pages
NA
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build on the previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with an outlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages.

Keywords
CRISPR CAS, Nagoya Protocol, antibiotic resistance, bacteriophage therapy, bacteriophages
Pubmed
Open Access
Yes
Create date
26/04/2018 16:46
Last modification date
21/08/2019 6:09
Usage data